The biotech era in late-stage drug R&D and marketing has arrived. And it looks like it’s here to stay
In a new report out looking over the landscape of drug R&D, IQVIA has been tracking the swelling role that startups play in the development game. And some of the conclusions may surprise you.
First and foremost, the number of active R&D compounds surged 37% in the 5 years from 2013 to 2018. And with biotechs able to operate increasingly independently of Big Pharma partners, the researchers determined that emerging companies now control 72% of the 2,853 late-stage drugs they tracked.
That’s up from 65% of a much smaller set of 2,083 therapies in 2013 and 52% of the 1,383 drugs in late-stage development in 2003. And close to half of the new drugs approved last year were launched by emerging biotechs, in stark contrast to the domination large companies once enjoyed in the marketing arena.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.